Parmax Pharma Ltd - 540359 - Intimation Of Re-Appointment Of Ms. Ami Shah As An Independent Director Of The Company.
Intimation of re-appointment of Ms. Ami Shah as an Independent Director of the Company.10-06-2023
10-06-2023
Parmax Pharma Ltd - 540359 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding loss of share certificate under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.06-06-2023
Parmax Pharma Ltd - 540359 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding loss of share certificate under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.01-06-2023
Parmax Pharma Ltd - 540359 - Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of The Company.
Outcome of the meeting of the Board of Directors of the Company.30-05-2023
Parmax Pharma Ltd - 540359 - Financial Results For Financial Year Ended 31 March 2023
Financial Results for financial year ended 31 March 202330-05-2023
Parmax Pharma Ltd - 540359 - Board Meeting Intimation for Intimation Of Board Meeting In Compliance With Reg. 29 Read With Reg. 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 ,inter alia, to consider and approve Intimation of Board Meeting in compliance with Reg. 29 read with Reg. 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.23-05-2023
Parmax Pharma Ltd - 540359 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding loss of share certificate under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.10-05-2023
Parmax Pharma Ltd - 540359 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding loss of share certificate under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.29-04-2023
Parmax Pharma Ltd - 540359 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyParmax Pharma Ltd 2CIN NO.L24231GJ1994PLC023504 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 3.94 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: YASH VORA Designation: COMPANY SECRETARY EmailId: [email protected] Name of the Chief Financial Officer: KEYUR VORA Designation: CHIEF FINANCIAL OFFICER EmailId: [email protected] Date: 29/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.29-04-2023